Endoloop Mediated Cardioplication to Treat Gastroesophageal Reflux Disease
Metal Clip and Endoloop Mediated Endoscopic Cardioplication (ECLC) for the Treatment of Gastroesophageal Reflux Disease (GERD):a Prospective Cohort Study
1 other identifier
interventional
35
0 countries
N/A
Brief Summary
Endoscopic full-thickness plication (EFTP) of cardia/fundus has been shown effective in treating GERD patients. However, EFTP requires proprietary equipment that are not available in many countries. Here, we designed a metal clip and endoloop mediated cardioplication (ECLC) procedure to achieve EFTP.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2023
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 22, 2023
CompletedFirst Posted
Study publicly available on registry
December 1, 2023
CompletedStudy Start
First participant enrolled
December 10, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 10, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 10, 2024
CompletedDecember 1, 2023
November 1, 2023
1 year
November 22, 2023
November 22, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The total score of the GERD-HRQL questionnaire
Questionnaire (GERD-HRQL) : Total Score: Calculated by summing the individual scores toquestions 1-15 Greatest possible score ( worst symptoms)= 75 Lowest possible score ( no symptoms)= 0 Heartburn Score: Calculated by summing the individual scores to questions 1-6 . Worst heartburn symptoms = 30 No heartburn symptoms= 0 Scores of ≤ 12 with each individual question not exceeding 2 indicate heartburn elimination. Regurgitation Score: Calculated by summing the individual scores to questions10-15. Worst regurgitation symptoms = 30 No regurgitation symptoms = 0 Scores of ≤ 12 with each individual question not exceeding 2 indicate regurgitation elimination.
at 3 month follow- up
Secondary Outcomes (6)
PPI usage
at 3, 6 and 12 month follow- up
Total score of GERD GerdQ questionnaire
at 3 month follow- up
Total score of GERD GerdQ and GERD HRQL questionnaires
at 6 and 12 month follow- up
Esophageal acid reflux and DeMeester score
at 3, 6, and 12 months follow- up
Healing status of reflux esophagitis and damaged mucosa
at 3, 6, and 12 months
- +1 more secondary outcomes
Study Arms (1)
endoloop mediated cardioplication (ECLC)
EXPERIMENTALThe ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
Interventions
The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
Eligibility Criteria
You may qualify if:
- Age 18-60 years old
- hiatal hernia ≤ 3cm
- Sliding hernia ≤ 3cm
- Classic reflux symptoms (heartburn, reflux) lasting for more than 6 months
- Daily PPIs ≥ 6 months
- Esophagitis (Los Angeles grade) Grade A, B, and C
- Gastroesophageal valve I-III grade (Hill grade)
- Pathological esophageal acid exposure (percentage of time with 24-hour esophageal PH\<4 \<4.2%)
- Normal or near normal esophageal movement (through manometry or impedance)
- The lower esophageal sphincter pressure (LESP) is between 5-15mmHg
- DeMeester score ≥ 14.7 or total reflux episodes\>73
- Patients who sign an informed consent form and voluntarily accept surgical expenses.
You may not qualify if:
- BMI\>35kg/m2
- ASA \>II
- Barrett's esophagus
- Hill IV level
- Large esophageal hiatal hernia\>3cm
- Esophagitis (Los Angeles grade) Grade D
- Peptic ulcer
- Primary esophageal motility disorders such as achalasia
- Previous esophageal or gastric surgery
- Uncontrolled systemic diseases
- Pregnancy or planned pregnancy within 1 year
- Have a history of cervical fusion surgery, esophageal diverticulum, scleroderma or dermatomyositis, eosinophilic esophagitis, liver cirrhosis or coagulation dysfunction, immune system diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Qilu Hospital of Shandong Universitylead
- Shandong Universitycollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
November 22, 2023
First Posted
December 1, 2023
Study Start
December 10, 2023
Primary Completion
December 10, 2024
Study Completion
December 10, 2024
Last Updated
December 1, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share